Change in self-reported somatic symptoms among patients in opioid maintenance treatment from baseline to 1-year follow-up

Table 1 Baseline characteristics, demographics, substance use, and other relevant variables for patients entering OMT (N = 283)

	Included (N = 176)	Lost to follow-up^f (N = 107)	p-value^a
Characteristics
Age, years	39 ± 10	39 ± 10	0.953
Male	127 (72)	75 (70)	0.813
Completed lower secondary education	83 (47)	41 (38)	0.170
Employed or enrolled in education	25 (15)	7 (7)	0.073
Treatment variables
Buprenorphine^b	43 (24)	28 (26)	0.853
Buprenorphine and Naloxone^c	99 (56)	55 (51)	0.502
Methadone	35 (20)	21 (20)	1.000
Other/unknown	0	3	-
Substance use related variables
Severity of dependence^d	10.35 ± 3.19	10.48 ± 2.83	0.735
Intravenous use past 6 months	130 (74)	78 (73)	0.968
Age at first intravenous use, years	19 ± 9	20 ± 8	0.873
No. substances past 6 months	3.8 ± 2.6	4.2 ± 3.3	0.268
Smoking (tobacco) past 6 months	166 (95)	93 (93)	0.805
Physical health
Number of somatic conditions	1 (1.1)	1.2 (1.1)	0.125
Burden of somatic symptoms	13.4 (9)	14.4 (9)	0.372
Mental health
Mental distress^e	1.25 ± 0.87	1.30 ± 0.85	0.609
Attempted suicide (lifetime)	66 (38)	47 (45)	0.282

Values are given as mean ± SD or n (%). ^aBased on t-tests and chi-squared, Yates’ correction for 2 × 2. ^bSubutex; ^cSuboxone; ^dSDS; ^eHSCL-25. ^fAlso includes cases that did not have any data on somatic symptoms.
Missing data, included group: Substances past 6 months, N = 3; Age intravenous, N = 4; Completed lower secondary education, N = 1; N = 4; Employed/edu, N = 4; Smoking, N = 1. Missing data lost to follow-up group: Employed/edu, N = 2; SDS, N = 1; Age intravenous, N = 1; Smoking, N = 1; Somatic symptoms burden, N = 1; Attempted suicide, N = 2.

ISSN: 1471-244X